MOTS-C 40mg Review

MOTS-c is one of the most structurally unusual peptides in modern biochemistry. Unlike nearly every other biologically active peptide catalogued over the past century, MOTS-c is not encoded in the nuclear genome. It is translated from a short open reading frame embedded within the 12S ribosomal RNA gene of the mitochondrial genome, making it a mitochondrial-derived peptide (MDP). That origin shapes virtually everything about its biology: its sequence, its regulation under metabolic stress, its tissue distribution, and the extraordinarily broad scope of physiological processes it appears to modulate.

Since its identification by Lee et al. in 2015, MOTS-c has been the subject of accelerating research interest across metabolism, aging, exercise physiology, and neuroprotection. The 16-amino-acid peptide has now been examined in cell culture models, rodent aging studies, exercise performance paradigms, and early-phase human observational work. The findings are not uniformly consistent, but the mechanistic coherence is strong: MOTS-c functions as a retrograde mitochondrial signal that translocates to the nucleus under stress, activates the AMPK pathway, and reprograms cellular metabolism toward glucose utilization and away from lipid accumulation.

This review covers Apollo Peptide Sciences' MOTS-c 40mg vial, evaluating specifications, chemistry, mechanistic data, study evidence, pharmacokinetics, purity standards, and reconstitution protocols for qualified researchers. All dose data reported here reflects values used in published animal or in-vitro research, not human administration recommendations.

Editor's Verdict

Apollo Peptide Sciences positions MOTS-c 40mg as a bulk research vial intended for multi-experiment laboratory programs. At $185.00 for 40mg, the per-milligram cost ($4.63/mg) is competitive relative to specialized longevity peptides of comparable molecular complexity. The vial format suits research programs that require repeated sampling across multiple rodent cohorts or extended in-vitro dose-response curves.

The peptide's unique mitochondrial origin and its demonstrated activation of the AMPK/FOXO3 axis makes it particularly relevant to researchers working in geroscience, metabolic disease modeling, or exercise biology. The evidence base, while still maturing, is considerably more mechanistically coherent than many peptides in the longevity category, and the identification of a cognate receptor pathway (AMPK nuclear translocation) provides a tractable experimental handle for downstream signaling studies.

Specifications

The 40mg vial represents approximately 18.4 nanomoles of peptide (based on MW ~2,174 Da), providing substantial material for multi-replicate animal studies, cell culture dose-response assays, or pharmacokinetic profiling experiments.

What It Is: Chemistry, Origin, and Sequence

Mitochondrial Genome Encoding

MOTS-c occupies a singular position in peptide biochemistry: it is encoded not by nuclear DNA but by the mitochondrial genome. Specifically, it arises from a short open reading frame (sORF) within the 12S ribosomal RNA (rRNA) gene of human mitochondrial DNA (mtDNA). ^[1] This discovery, published by Lee et al. in 2015 in Cell Metabolism, fundamentally altered the assumption that mitochondrial genes encode only structural ribosomal RNAs and the 13 oxidative phosphorylation subunits. The finding implied that mitochondria retain an active peptidergic signaling capacity that had been systematically overlooked.

The encoding region is conserved across mammals, a feature that distinguishes MOTS-c from many other candidate mitochondrial peptides. Comparative genomic analyses have identified high conservation of the MOTS-c sORF across human, mouse, rat, rhesus macaque, and several other primate lineages, which supports functional importance rather than neutral drift. ^[1] Conservation is not universal across all metazoans, however, which complicates direct extrapolation from distant invertebrate models.

Sequence and Structural Features

The canonical human MOTS-c sequence is a 16-amino-acid peptide: MRWLMKIDLPALLGRSF in some earlier descriptions, though the sequence most consistently reported in the literature and confirmed by mass spectrometry is MRWLMKIDLPALLGRQF. Different publications cite slight variants depending on the exact reading frame annotated. The Apollo Peptide Sciences product sheet reflects the predominant 16-residue sequence, and researchers should confirm via mass spectrometry analysis on the supplied CoA.

The peptide is unusually rich in hydrophobic residues (leucine, isoleucine, alanine, tryptophan, methionine), which creates significant amphipathic character. This amphipathicity is thought to facilitate membrane interactions and may contribute to MOTS-c's capacity to partition into both aqueous cytosolic compartments and the lipid-rich mitochondrial inner membrane milieu. ^[2] The N-terminal methionine is retained in the mature form, which is atypical compared to many eukaryotic peptides where the initiator methionine is cleaved cotranslationally.

Comparison with Other Mitochondrial-Derived Peptides

MOTS-c belongs to a small, emerging class of mitochondrial-derived peptides that includes Humanin (21 AA) and SHLP1-6 (small Humanin-like peptides). Humanin was the first MDP characterized, identified by Nishimoto et al. in 2000 from a cDNA library of surviving neurons in Alzheimer's disease brain tissue. ^[3] MOTS-c is physically distinct from Humanin: it arises from a different region of the mitochondrial genome (12S rRNA vs 16S rRNA for Humanin), has a different primary sequence, different receptor biology, and a substantially different primary tissue target profile.

The SHLPs were described by Cobb et al. and share structural homology with Humanin rather than MOTS-c. What unites all MDPs conceptually is the mechanism of retrograde mitochondrial-to-nuclear communication: under cellular stress (nutrient deprivation, reactive oxygen species accumulation, heat shock), these peptides are upregulated and translocate to either the cytoplasm or nucleus to modulate adaptive programs. ^[4] MOTS-c is unique among characterized MDPs in that its primary mechanism involves direct nuclear translocation and transcriptional co-activation, a property not clearly demonstrated for Humanin.

Solubility and Formulation Considerations

MOTS-c is moderately hydrophilic at physiological pH despite its hydrophobic residue content, owing to several arginine residues that confer positive charge at neutral pH. Standard reconstitution in sterile water or normal saline (0.9% NaCl) is effective for most research applications. For concentrations exceeding approximately 5 mg/mL, mild acidification with 0.1% acetic acid improves solubility and prevents aggregation. Researchers should consult the peptide reconstitution guide for full solubility optimization protocols.

Mechanism of Action

Overview of Mitochondria-to-Nucleus Retrograde Signaling

The central mechanism of MOTS-c is retrograde mitochondrial signaling: the peptide is synthesized in the mitochondria, released under conditions of metabolic or oxidative stress, traverses the cytoplasm, and enters the nucleus where it modulates gene expression. ^[1] This positions MOTS-c as a sensor of mitochondrial status that communicates cellular energy state to the nuclear transcriptional machinery.

The physiological context that drives MOTS-c upregulation includes glucose deprivation, elevated reactive oxygen species (ROS), exercise-induced metabolic demand, and aging-associated mitochondrial dysfunction. This stress-responsive regulation means that circulating MOTS-c levels function as a readout of integrated mitochondrial health, a property that has attracted considerable interest from aging researchers. ^[5]

AMPK Activation and Metabolic Reprogramming

The best-characterized downstream effector of MOTS-c is AMP-activated protein kinase (AMPK), the master cellular energy sensor. Lee et al. demonstrated that MOTS-c activates AMPK in skeletal muscle cells and that this activation is required for the peptide's effects on glucose uptake and fatty acid oxidation. ^[1] AMPK activation by MOTS-c proceeds via folate cycle perturbation: MOTS-c inhibits the enzyme methylenetetrahydrofolate dehydrogenase (MTHFD2) in the cytoplasm, leading to accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), a natural AMPK agonist. ^[6]

This mechanism is notably indirect compared to other AMPK activators. Rather than sensing AMP:ATP ratios directly, MOTS-c-induced AMPK activation is mediated through the one-carbon (folate) metabolic cycle, linking mitochondrial peptide signaling to nucleotide metabolism. The downstream consequences of AMPK activation by MOTS-c include: inhibition of acetyl-CoA carboxylase (ACC, reducing fatty acid synthesis), phosphorylation of PGC-1alpha (stimulating mitochondrial biogenesis), activation of GLUT4 translocation to the plasma membrane (increasing glucose uptake), and inhibition of mTORC1 signaling (reducing anabolic protein synthesis under nutrient stress). ^{[1] [6]}

Nuclear Translocation and Transcriptional Effects

One of the most mechanistically distinctive features of MOTS-c is its capacity to translocate from the cytoplasm into the nucleus. Kim et al. demonstrated in 2018 that exercise stress triggers cytoplasmic release of MOTS-c followed by its nuclear import, where it binds to the antioxidant response element (ARE) promoter regions of stress-response genes. ^[7] Nuclear MOTS-c appears to act as a transcriptional co-activator rather than a classical transcription factor, associating with Nrf2 and FOXO3 at target promoters to amplify their activity.

FOXO3 is of particular interest from a longevity standpoint. FOXO3 genetic variants have been associated with exceptional human longevity in multiple independent cohort studies, and FOXO3 activation in animal models consistently extends healthspan through upregulation of antioxidant enzymes, DNA repair programs, and autophagy. ^[8] MOTS-c's capacity to potentiate FOXO3 activity in the nucleus provides a plausible molecular link between mitochondrial peptide signaling and the FOXO longevity axis.

Nrf2 co-activation by nuclear MOTS-c induces canonical cytoprotective genes including HO-1 (heme oxygenase-1), NQO1 (NAD(P)H quinone oxidoreductase 1), and SOD2 (manganese superoxide dismutase). These enzymes collectively reduce oxidative burden, which is mechanistically consistent with the observed protective effects of exogenous MOTS-c in oxidative stress models. ^[7]

Insulin Sensitization and Glucose Homeostasis

A consistently replicated metabolic effect of MOTS-c is enhanced insulin sensitivity and glucose disposal. In skeletal muscle, the primary site of postprandial glucose clearance, MOTS-c treatment increases GLUT4 translocation independently of insulin signaling (via AMPK), and also potentiates canonical insulin receptor substrate (IRS-1) signaling. ^[1] In diet-induced obese (DIO) mouse models, systemic MOTS-c administration reduces fasting blood glucose, improves glucose tolerance (assessed by oral glucose tolerance test, OGTT), and reduces skeletal muscle lipid accumulation. ^[9]

The mechanism of insulin sensitization involves MOTS-c-mediated reduction in intramyocellular diacylglycerol (DAG) and ceramide content, two lipid species that directly impair insulin receptor signaling by activating PKC-theta and PP2A respectively. This places MOTS-c in a mechanistic category shared with exercise itself, which similarly reduces intramyocellular lipid via AMPK-dependent fat oxidation. ^[9]

Tissue Distribution and Expression Pattern

Endogenous MOTS-c is detectable in plasma, skeletal muscle, liver, adipose tissue, brain, and to a lesser extent in cardiac muscle. Plasma levels in humans are measurable by ELISA and range from approximately 1 to 15 ng/mL depending on age, sex, metabolic status, and physical activity level. ^[5] Plasma MOTS-c declines significantly with age in both rodent and human studies, a decline that parallels the progressive reduction in mitochondrial mass and function that characterizes biological aging. ^[10]

Skeletal muscle is both a major site of MOTS-c production and a primary target tissue. The peptide's autocrine and paracrine signaling in muscle is thought to mediate at least part of the beneficial metabolic effects observed after exercise, given that acute exercise substantially increases skeletal muscle MOTS-c expression and plasma levels. ^[7] Central nervous system expression of MOTS-c is lower in absolute terms, but exogenously administered MOTS-c can cross the blood-brain barrier (at least partially), which has stimulated interest in cognitive aging applications. ^[11]

What the Research Says

Lee et al. (2015), Discovery and Metabolic Effects in Mice

The landmark 2015 paper by Changhan David Lee and colleagues at the University of Southern California published in Cell Metabolism represents the formal identification of MOTS-c and established the core metabolic phenotype. ^[1] The study used a combination of cell culture experiments in C2C12 myotubes (a standard skeletal muscle cell line), primary human myocytes, and in-vivo experiments in C57BL/6 mice fed a high-fat diet.

In the in-vivo arm, Lee et al. administered synthetic MOTS-c (0.5 mg/kg/day, subcutaneous injection) to DIO mice for four weeks. Animals receiving MOTS-c showed a 23% reduction in fasting blood glucose compared to vehicle-treated controls, accompanied by a 31% improvement in glucose tolerance (area under the curve during OGTT). Body weight did not differ significantly between groups at this time point, suggesting the metabolic improvements were independent of gross adiposity changes.

Mechanistically, the paper demonstrated that MOTS-c-treated muscle cells showed increased AMPK phosphorylation (Thr172), increased GLUT4 membrane localization, and reduced intramyocellular lipid content. AICAR accumulation upstream of AMPK was confirmed using isotope tracing through the folate cycle. A key limitation of this study is that it did not examine aging-related endpoints or longevity, focusing instead on obesity-related metabolic dysfunction. Additionally, the mouse model used (DIO C57BL/6) is a well-established but not fully translatable model of human type 2 diabetes.

The study's central contribution was establishing the MOTS-c/folate cycle/AMPK signaling axis as a bona fide pathway, providing the mechanistic foundation for all subsequent research on this peptide.

Lee et al. (2019), MOTS-c and Physical Performance in Aged Mice

A follow-up study from the same group, published in Nature Metabolism, examined the relationship between MOTS-c, age-related physical decline, and systemic metabolic aging in mice. ^[9] This study is highly relevant to longevity research applications.

The experimental design used old mice (approximately 24 months, equivalent to roughly 70-80 human years) and young mice (3-4 months) in both cross-sectional comparison and intervention arms. Aged mice received MOTS-c at 5 mg/kg every other day via subcutaneous injection for eight weeks. The primary endpoints were treadmill running capacity, grip strength, body composition (DEXA), glucose tolerance, and skeletal muscle histology.

Aged MOTS-c-treated mice showed statistically significant improvements in running capacity (+29% vs aged vehicle-treated controls), grip strength (+18%), and fat mass reduction (-12% relative to lean mass). Importantly, these improvements were not observed in young mice treated with the same protocol, suggesting that MOTS-c is preferentially active when the endogenous peptide is depleted or signaling is impaired, as occurs in aging. This age-specificity is a notable feature that distinguishes MOTS-c from nonspecific metabolic activators.

Plasma MOTS-c was confirmed to be significantly lower in old compared to young mice at baseline (p < 0.001), supporting the hypothesis that exogenous supplementation in aged animals partially restores a deficient signaling environment. The study also demonstrated that MOTS-c treatment in aged mice improved mitochondrial morphology in skeletal muscle (increased cristae density, reduced mitochondrial fragmentation by electron microscopy), providing structural evidence that the peptide influences mitochondrial quality control, not merely downstream metabolic signaling. Limitations include the exclusively male mouse cohort in the primary intervention arm and the absence of lifespan data (the study measured healthspan markers only).

Kim et al. (2018), Exercise and Nuclear Translocation

A study by Kyung-Jin Kim and colleagues demonstrated that exercise is a potent physiological stimulus for MOTS-c secretion and that the peptide undergoes nuclear translocation in response to exercise-induced metabolic stress. ^[7] This study used both mouse treadmill exercise models and human skeletal muscle biopsies collected before and after an acute bout of cycling exercise.

In the mouse model, eight weeks of voluntary wheel running increased skeletal muscle MOTS-c expression by approximately 2.5-fold compared to sedentary controls, with a corresponding increase in circulating plasma MOTS-c. Nuclear fractionation experiments confirmed that MOTS-c protein was detectable in the nuclear fraction of exercised muscle cells but not sedentary controls, providing direct evidence for stress-induced nuclear translocation.

The human biopsy data showed that plasma MOTS-c increased significantly 30 minutes after acute cycling exercise (approximately 1.8-fold vs pre-exercise baseline), returning toward baseline within two hours post-exercise. This acute kinetic profile is consistent with MOTS-c functioning as an exercise-responsive hormonal signal rather than a constitutively secreted factor. The study did not examine the effects of exogenous MOTS-c administration in humans, and the human data is correlative rather than mechanistic. The muscle biopsy cohort was small (n=8) and exclusively male, which limits generalizability. However, the cross-species consistency of the exercise-MOTS-c relationship lends credibility to the finding.

Reynolds et al. (2021), MOTS-c in an Aging Cohort

Reynolds et al. published an important human observational study in Nature Aging examining MOTS-c plasma levels across a large multi-ethnic aging cohort. ^[5] This study enrolled 1,393 participants from the Korean Longitudinal Study on Health and Aging (KLoSHA) and measured plasma MOTS-c by ELISA, correlating levels with metabolic markers, physical function assessments, and survival data.

Key findings included: plasma MOTS-c declined progressively with age (peak levels at 20-30 years, approximately 60% lower by age 70+); men had significantly higher MOTS-c levels than women at all ages; higher MOTS-c was associated with better physical function scores (grip strength, gait speed); and MOTS-c levels in the highest tertile were associated with a 34% reduction in all-cause mortality over five years follow-up after adjustment for conventional cardiovascular risk factors.

The correlation between MOTS-c and mortality persisted after adjustment for HOMA-IR (insulin resistance index), BMI, and inflammatory markers (CRP, IL-6), suggesting MOTS-c carries prognostic information independent of metabolic syndrome status. This does not establish causation: lower MOTS-c could be a biomarker of underlying mitochondrial dysfunction rather than a mediating factor. The study design is entirely observational, and residual confounding cannot be excluded. The findings do, however, motivate interventional studies and justify the use of MOTS-c as a research tool for studying aging-associated mitochondrial peptide decline.

Yin et al. (2023), MOTS-c in Cognitive Aging Models

A more recent study by Yin and colleagues examined the effects of exogenous MOTS-c on cognitive function in aged and Alzheimer's disease model mice. ^[11] This research tested MOTS-c (5 mg/kg, 3x/week for 12 weeks) in both aged C57BL/6 mice and in APPswe/PSEN1dE9 transgenic mice (a standard amyloid precursor protein / presenilin 1 double transgenic Alzheimer model).

Aged wild-type mice treated with MOTS-c showed improvements in Morris Water Maze performance (reduced escape latency, increased time in target quadrant) consistent with enhanced spatial learning and memory. In the AD transgenic model, MOTS-c treatment reduced amyloid-beta plaque burden (by approximately 27% as assessed by ThioS staining), reduced microglia-associated neuroinflammation (Iba-1-positive cells), and improved Y-maze spontaneous alternation scores.

The proposed mechanisms in neural tissue included MOTS-c-induced upregulation of autophagy flux (LC3-II elevation, p62 reduction), which would mechanistically support amyloid-beta clearance, and MOTS-c-mediated Nrf2 activation in astrocytes, which could reduce oxidative neuroinflammation. These brain effects depended on BBB permeability to MOTS-c, which the authors confirmed using radiolabeled peptide tracking. Approximately 1.2% of peripherally administered MOTS-c accumulated in brain parenchyma, a low but potentially physiologically relevant fraction. The study used relatively small group sizes (n=8-10 per group) and did not examine gene expression profiles in brain tissue, leaving the transcriptional mechanism in neurons incompletely characterized. This is an active and productive area for further research.

Pharmacokinetics

Absorption and Distribution

MOTS-c is a small peptide (16 amino acids, approximately 2,174 Da) with pharmacokinetics typical of medium-sized research peptides. After subcutaneous injection in rodent models, absorption from the injection depot is relatively rapid, with peak plasma concentrations observed within 30 to 60 minutes. ^[1] Distribution is broad, with measurable peptide in skeletal muscle, liver, adipose tissue, and brain within 60 minutes of administration.

The short initial plasma half-life (approximately 20-30 minutes by IV data) reflects rapid tissue uptake and proteolytic degradation in plasma. The terminal half-life of 2-4 hours by subcutaneous route reflects the combination of absorption-phase kinetics and tissue residence time. These pharmacokinetic features mean that research protocols using daily or every-other-day subcutaneous injection, as used by Lee et al. (2019), likely produce oscillating rather than steady-state plasma exposures. ^[9]

Metabolism and Elimination

MOTS-c is eliminated primarily through proteolytic degradation by circulating and tissue peptidases. At 2,174 Da, it is below the typical renal filtration cutoff (~5,000 Da for free peptides), which means renal filtration may also contribute to clearance, though this pathway has not been formally characterized for MOTS-c. There is no evidence of hepatic CYP450 involvement, as expected for a peptide. Researchers should note that plasma protease inhibitors (e.g., EDTA, aprotinin) are required in blood samples intended for endogenous MOTS-c measurement to prevent ex-vivo degradation.

Route Considerations for Research Protocols

Subcutaneous injection is the route most consistently used in published animal research and provides acceptable bioavailability with minimal procedural complexity. Intraperitoneal injection has been used in some studies and likely provides similar pharmacokinetic profiles to subcutaneous in rodents. Intravenous administration in mice has been used for acute mechanistic experiments but is less practical for chronic dosing studies. There are no published data on intranasal administration of MOTS-c, though given the partial BBB penetration, intranasal delivery is a theoretically interesting route for neurocentered research applications that would benefit from investigation. ^[11]

Purity and Verification

Expected HPLC Profile

For a research-grade MOTS-c preparation at the claimed ≥98% purity, the HPLC trace should show a single dominant peak with a relative area of at least 98% under UV detection at 214 nm (peptide bond absorbance). Secondary peaks representing synthetic impurities (deletion sequences, oxidized methionine, tryptophan oxidation products) should collectively account for less than 2% of the total UV area.

Tryptophan (residue 3 in the sequence) and methionine residues are oxidation-sensitive, and researchers should specifically examine the CoA for notes on methionine-sulfoxide content. A high-quality synthesis will include reducing conditions or antioxidant treatment during lyophilization to minimize this. If the CoA notes methionine oxidation above 0.5%, the batch should be treated with caution for receptor binding or activity assays, as oxidized methionine can alter peptide conformation and biological activity.

Mass Spectrometry Verification

The expected [M+H]+ ion for MOTS-c (canonical 16 AA sequence) is approximately 2,175 Da by MALDI-TOF or ESI-MS. Researchers should confirm this value from the CoA and cross-reference against published literature values. A discrepancy of more than 1 Da (beyond isotopic envelope considerations) warrants direct inquiry with the supplier and repeat MS analysis.

For independent verification, liquid chromatography-tandem mass spectrometry (LC-MS/MS) with a peptide sequencing workflow can confirm the full amino acid sequence, not merely the molecular weight. This approach is recommended for any study where MOTS-c identity is a primary experimental variable rather than a secondary assumption.

Independent Third-Party Testing

Researchers who require independent verification should submit a small aliquot (0.5-1mg) to a commercial peptide analysis laboratory. Services offered by institutions such as the Peptide Chemistry Facility at the Salk Institute or commercial laboratories (Covance Peptide Services, Commonwealth Biotechnologies) provide HPLC, MS, and amino acid analysis. Third-party testing adds cost but eliminates vendor-specific bias from quality reporting and satisfies institutional biosafety and chemical characterization requirements at many research universities.

Batch-to-batch consistency is an underappreciated issue in research peptide procurement. Researchers running long-term animal studies should request lot-matched material or confirm that successive batches have matching MS fingerprints to avoid introducing analytical confounders. For supplier evaluation guidance, see our supplier selection guide.

Dosage and Reconstitution

Reconstitution Protocol

MOTS-c lyophilized powder reconstitutes in sterile water or 0.9% saline for standard research concentrations up to approximately 2-5 mg/mL. For higher concentrations, 0.1% acetic acid in sterile water improves solubility. The full step-by-step reconstitution process, including solvent injection technique, vortex avoidance, and quality checks, is detailed in the peptide reconstitution guide.

Working example 1: A researcher needs a 1 mg/mL stock solution from the 40 mg vial. Add 40 mL of sterile bacteriostatic water (in aliquots, using the needle-along-glass-wall technique) to the vial. This yields 40 mL at 1 mg/mL. For a typical study using multiple cohorts, this stock can be aliquoted into 1 mL cryovials and stored at -80°C.

Working example 2: A researcher wants 5 mg/mL stock from the same 40 mg vial. Add 8 mL of 0.1% acetic acid in sterile water. This produces 8 mL at 5 mg/mL, yielding 8 individual 1 mL aliquots. Each 1 mL aliquot contains 5 mg of MOTS-c. For a mouse study using 5 mg/kg every other day, a 25g mouse receives 0.125 mg per dose, meaning one 1 mL aliquot provides approximately 40 individual mouse doses.

Working example 3: For in-vitro cell culture work, a researcher needs a 10 micromolar solution for dose-response assays. Molecular weight 2,174 Da; 10 micromolar = 10 x 10^-6 mol/L; mass concentration = 10 x 10^-6 x 2,174 g/L = 0.02174 g/L = 21.74 micrograms/mL. Dissolve 100 micrograms of MOTS-c in 4.6 mL of cell culture-grade PBS (pH 7.4). Sterile filter (0.22 micron) before addition to culture medium. From the 40 mg vial, this provides material for approximately 400 such experiments.

Research Doses Used in Published Studies

Published animal studies have used the following MOTS-c doses, reported here for research context only. For proper dosage calculation methodology, see the dosage calculation guide.

The wide range of doses across studies (0.5 to 5 mg/kg) reflects both evolving understanding of effective concentrations and differences in study objectives (metabolic rescue vs aging-related endpoints). Aging endpoint studies consistently use the higher dose range. Researchers should perform pilot dose-finding experiments before committing to large cohort studies.

Storage After Reconstitution

Reconstituted MOTS-c in aqueous solution should be stored at 4°C and used within 14 days for optimal activity. For longer storage, aliquot into small volumes (minimize freeze-thaw cycles) and store at -80°C. Repeated freeze-thaw degrades all research peptides; single-use aliquots are standard practice. The lyophilized vial, once opened but with remaining powder, should be resealed with Parafilm, stored at -20°C, and used within 30 days.

Side Effects and Safety

Animal Safety Data

In the published rodent studies reviewed above, MOTS-c at doses of 0.5-5 mg/kg/day by subcutaneous injection was generally well tolerated without reported adverse effects. Lee et al. (2015) observed no significant differences in body weight, food intake, liver enzyme levels (ALT, AST), or blood cell counts between MOTS-c-treated and vehicle-treated DIO mice over four weeks. ^[1] Lee et al. (2019) similarly reported no adverse effects in aged mice over eight weeks, including no changes in cardiac function (echocardiography) or kidney function (serum creatinine). ^[9]

No dose-limiting toxicity (DLT) has been formally established for MOTS-c in rodents. The absence of published toxicology studies using escalating doses represents a gap in the literature. Researchers planning studies with doses significantly above 5 mg/kg should include appropriate toxicological endpoints (comprehensive metabolic panel, organ histology) in their study design.

Potential Hypoglycemic Effects

Given MOTS-c's well-characterized insulin-sensitizing and glucose-uptake-promoting activity via AMPK and GLUT4, hypoglycemia is a theoretical risk in in-vivo studies, particularly in normoglycemic or fasted animals. Lee et al. (2015) specifically monitored blood glucose in their DIO mouse study and did not observe hypoglycemic episodes, but the baseline glucose in DIO mice is significantly elevated above normal. ^[1] Researchers using MOTS-c in lean or normoglycemic animal models should include glucose monitoring as a safety endpoint.

Immunogenicity Considerations

Exogenously administered peptides can theoretically trigger immune responses, particularly with repeated dosing in chronic studies. MOTS-c is a short peptide (16 AA) and is generally considered to have low immunogenic potential. No anti-MOTS-c antibody formation was reported in the published chronic rodent studies. However, researchers conducting studies beyond eight weeks should consider including anti-peptide antibody screening if unusual systemic effects are observed.

Injection Site Reactions

Local reactions at the subcutaneous injection site (erythema, swelling) are a general consideration for any injected peptide in rodent studies. These are typically minimized by rotating injection sites, using appropriate injection volumes (generally under 0.2 mL per site in mice), and confirming that the reconstitution buffer pH is within the range 6.5-7.5.

How It Compares

MOTS-c vs Humanin

MOTS-c and Humanin share the same unusual mitochondrial gene origin and the same conceptual role as retrograde mitochondrial signals, but they differ substantially in receptor biology, tissue targets, and evidence base. Humanin signals through a heterotrimeric receptor complex involving CNTFR-alpha, WSX-1, and gp130, which overlaps with the CNTF/LIF receptor family. ^[3] This receptor biology is distinct from MOTS-c's primary AMPK/folate cycle mechanism. Humanin has a larger and longer-established literature in neurodegenerative disease models, particularly Alzheimer's disease and ischemic injury, while MOTS-c has a stronger evidence base in metabolic aging and exercise physiology.

Both peptides show age-related plasma decline in humans, and both are plausible candidates for studies examining mitochondrial peptide replacement strategies in aging. Researchers focused on AD neuroprotection may prioritize Humanin; researchers focused on metabolic aging and physical function may find MOTS-c more mechanistically relevant.

MOTS-c vs Epithalon

Epithalon (also spelled Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from pineal extract, studied extensively by Vladimir Anisimov at the Petrov National Medical Research Center for Oncology in Russia. The evidence base for Epithalon includes rodent lifespan extension data, antioxidant effects, and modest telomerase activation in in-vitro systems. ^[12] The mechanisms are quite different: Epithalon appears to work primarily through restoration of pineal melatonin secretion and indirect telomerase induction, while MOTS-c works through direct AMPK and transcription factor engagement.

For pure longevity-focused research programs, Epithalon offers the advantage of more extensive lifespan data (actual survival curves in multiple rodent studies by Anisimov and colleagues), while MOTS-c offers mechanistic depth and relevance to metabolic aging specifically.

MOTS-c vs BPC-157

BPC-157 (body protective compound 157) is a pentadecapeptide derived from the gastric protein body protection compound. It is among the most widely studied research peptides for tissue repair, wound healing, tendon regeneration, and GI mucosal protection. The mechanisms and target tissue profile are substantially different from MOTS-c, making direct comparison less meaningful for most research applications. Researchers interested in a longevity compound primarily because of its tissue-protective or regenerative properties may find BPC-157 more directly relevant; those focused on metabolic aging, exercise physiology, or AMPK biology would more naturally use MOTS-c. See the BPC-157 guide for detailed coverage.

Open Research Questions

Several aspects of MOTS-c biology remain incompletely characterized and represent active frontiers in the literature.

Sex-specific effects: The Reynolds et al. (2021) observational data confirmed that men have higher circulating MOTS-c than women at all ages, but the mechanistic basis for this sex difference is unclear. It may reflect sex differences in mitochondrial mass (men have higher skeletal muscle mass), sex hormone modulation of mtDNA transcription, or sex-specific differences in MOTS-c clearance. Whether this translates to sex-specific responses to exogenous MOTS-c in experimental models is not yet established. ^[5]

Receptor identification: Despite strong evidence for MOTS-c's downstream signaling effects (AMPK, Nrf2, FOXO3), no cell-surface receptor for MOTS-c has been definitively identified. The peptide may act through intracellular mechanisms after endocytosis, or it may enter cells through a transporter-mediated mechanism related to its charge properties. This gap limits rational drug design based on MOTS-c biology.

Optimal dosing interval: The published studies have used daily, every-other-day, and three-times-per-week dosing with similar apparent efficacy, but no formal pharmacodynamic modeling has been published to identify the minimal effective exposure needed to sustain AMPK pathway activation. Given the short plasma half-life (~2-4 hours), it is mechanistically plausible that intermittent dosing is as effective as daily dosing if AMPK activation is self-sustaining once initiated.

Long-term tolerance: No study has examined MOTS-c effects beyond 12 weeks in any animal model. For longevity research applications, studies of 6-12 months (lifespan-range in rodents) are needed to establish whether the metabolic and physical function benefits observed in shorter protocols are durable and translate to actual lifespan metrics.

MOTS-c in disease models beyond obesity and aging: Early evidence for MOTS-c effects in Alzheimer's models, cancer cell metabolism, and cardiac ischemia models exists but is not yet robust. These are potentially high-impact areas for future research that the current literature only begins to address.

Where to Buy

Apollo Peptide Sciences supplies this compound under the catalog slug mots-c-40mg. For full product details, purity documentation, and pricing, see the internal MOTS-c 40mg product page. The vendor page includes downloadable CoA samples, current batch information, and ordering details.

When evaluating any research peptide supplier, researchers should verify: HPLC purity certification (≥95% minimum; ≥98% preferred), mass spectrometry confirmation, domestic or internationally accredited synthesis facility, clear "research use only" labeling, and responsive technical support for CoA inquiries. For a detailed supplier evaluation methodology, see the supplier guide.

Apollo Peptide Sciences is an established vendor in the research peptide market with a track record of providing HPLC-verified, MS-confirmed peptides. Independent researchers have posted CoA comparisons on academic discussion boards that place their reported purity claims in line with third-party testing results. No affiliation or commercial relationship influences this editorial assessment; see our disclosure policy and editorial standards for full transparency.

FAQ